Nel


Alkaline's dry spell prolongs Nel's suffering with yet another underwhelming result

15/10/26 -"Nel continued its dismal run of results as a perennially shrinking Alkaline order book weighs on headline numbers despite sustained positive momentum in PEM. The group reduced costs further but these ..."

Pages
45
Language
English
Published on
15/10/26
You may also be interested by these reports :
15/10/26
Nel continued its dismal run of results as a perennially shrinking Alkaline order book weighs on headline numbers despite sustained positive momentum ...

15/10/26
Following the transfer of coverage, we have reset the operating model of the group, leading to a downward revision in our forecasts and subsequent ...

15/10/26
KION released preliminary Q3 26 figures this morning and lowered its FY26 outlook. Q3 revenue came in at c.€2,835m, broadly in line with consensus, ...

14/10/26
Bossard delivered impressive Q3 sales growth of 11.2% in local currencies, led by Asia and semiconductor demand. FY26 sales guidance of CHF ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO